![]() |
市場調查報告書
商品編碼
1494621
個人化醫療市場:按產品、應用和最終用戶分類 - 全球預測 2024-2030Personalized Medicine Market by Product (Personalized Medical Care, Personalized Medicine Diagnostics, Personalized Medicine Therapeutics), Application (Antiviral, Cardiology, Immunology), End Users - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年個人化醫療市場規模為5,421億美元,預計2024年將達5,755億美元,2030年將達8,520.2億美元,複合年成長率為6.67%。
個人化醫療是客製化的醫療保健,根據個別患者的情況(包括遺傳、分子、環境和生活方式因素)量身訂做治療方案。這種適應性醫學充分利用基因組學、即時診斷等關鍵技術,涵蓋診斷、治療、個體化醫療、個人化營養指導等廣泛應用。該市場的成長歸因於人工智慧等技術進步以及由於全球個人慢性病盛行率不斷上升而需要個人化健康干預措施。然而,研究和基礎設施開發的高額初始投資,以及與使用個人化醫療相關的隱私問題,可能會阻礙市場成長。人工智慧、行動醫療技術和再生醫學提供了大量可以改變治療模式的創新機會。此外,全球健康資料整合的增加以及公眾和專業人士參與的增加可能會進一步促進個人化醫療解決方案的廣泛採用。
主要市場統計 | |
---|---|
基準年[2023] | 5421億美元 |
預測年份 [2024] | 5755億美元 |
預測年份 [2030] | 8520.2億美元 |
複合年成長率(%) | 6.67% |
區域洞察
在北美,政府和私營部門的大量投資正在推動市場發展,在腫瘤學和心臟病學等領域明顯傾向於個人化醫療。該地區強調將個人化醫療納入公共衛生保健系統。在南美洲,特別是在巴西、阿根廷和智利,基因檢測的普及使得預防醫學和量身定做的治療策略成為可能。當地研究機構和全球研究公司之間合作的增加也補充了這種成長。在歐盟委員會的支持以及與個人化醫療相關的倫理和法律的大力關注下,歐盟 (EU) 對個人化醫療研究表現出越來越濃厚的興趣。中東和非洲在這一領域正在興起,以色列和沙烏地阿拉伯在發展個體化醫療方面取得了長足進步,各國政府專注於醫療改革和教育。南非正在利用其獨特的遺傳多樣性為世界其他地區開拓基因組醫學計劃。亞太地區在透過個人化醫療策略利用技術力來解決遺傳疾病和癌症負擔沉重的老齡化人口方面正在取得快速進展。該地區的消費者越來越願意參與基因檢測和個人化醫療保健計劃。政府策略性舉措著重於基因組學和個人化醫療解決方案,以解決遺傳疾病和各種癌症的高盛行率。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在個人化醫療市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對個人化醫療市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在個人化醫療市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。這項關鍵評估涉及對組織的資源、能力和整體績效的徹底分析,以確定核心優勢和需要改進的領域。
[183 Pages Report] The Personalized Medicine Market size was estimated at USD 542.10 billion in 2023 and expected to reach USD 575.50 billion in 2024, at a CAGR 6.67% to reach USD 852.02 billion by 2030.
Personalized medicine is customized healthcare that aligns medical treatments with individual patient profiles, which include genetic, molecular, environmental, and lifestyle factors. This adaptive practice spans diverse applications, including diagnostics, therapeutics, tailored medical care, and customized nutritional guidance, using key technologies such as genomics and real-time diagnostics. Growth in this market is due to advancements in technology, such as AI, and the necessity of personalized health interventions due to the increasing prevalence of chronic disease rates among individuals around the globe. However, high initial cost investment for research and infrastructure and privacy concerns associated with the use of personalized medicine use can hinder market growth. Opportunities for innovation abound in AI, mobile health technologies, and regenerative medicine, which can shift therapeutic paradigms. Additionally, the push towards global health data integration and heightened public and professional engagement can further encourage the broad adoption of personalized health solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 542.10 billion |
Estimated Year [2024] | USD 575.50 billion |
Forecast Year [2030] | USD 852.02 billion |
CAGR (%) | 6.67% |
Regional Insights
In North America, the market is propelled by substantial investments from both government and private sectors, with a clear inclination towards personalized treatments observed in fields such as oncology and cardiology. The region emphasizes the integration of personalized medicine into public healthcare systems. In South America, mainly Brazil, Argentina, and Chile, the surge in genetic testing enabled preventative care and tailored treatment strategies. This growth is complemented by increasing collaborations between local research entities and global research firms. European Union showed a growing interest in personalized medical research, with backing from the European Commission and an acute focus on the ethical and legal dimensions associated with personalized medicine. The Middle East and Africa are emerging in this arena, with Israel and Saudi Arabia making significant strides in the development of customized medicine by increasing governmental focus on healthcare reform and education. South Africa is leveraging its unique genetic diversity to pioneer genomic medicine projects for the rest of the world with active investment for global organizations in healthcare and research. The Asia Pacific region showcases rapid progress with technological prowess to cater to its aging population through personalized healthcare strategies for its high burden of genetic diseases and cancer. The region is showing increased consumer readiness to participate in genetic testing and personalized healthcare programs. The government's strategic initiatives emphatically support genomics and personalized treatment solutions in response to the high prevalence of genetic diseases and various cancers within the population.
Market Insights
The market dynamics represent an ever-changing landscape of the Personalized Medicine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Personalized Medicine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Personalized Medicine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
AstraZeneca Acquires Fusion Pharmaceuticals for Personalized Cancer Medicine
AstraZeneca acquired Fusion Pharmaceuticals, a biopharmaceutical company specializing in next-generation radioconjugates, in a deal potentially worth up to USD 2400 million. This acquisition represents a pivotal development in the cancer treatment landscape, with Fusion enhancing AstraZeneca's capacity to deliver innovative, patient-specific therapies. [Published On: 2024-03-19]
CurifyLabs Acquires Key 3D Printing IP from Mehta Heino Industries to Advance Personalized Medicine Solutions
CurifyLabs, a health technology company, acquired significant intellectual property from Mehta Heino Industries Oy. This acquisition aims to enhance CurifyLabs' capabilities in producing personalized medicines for hospitals and compounding pharmacies, focusing particularly on pediatric populations. This acquisition is pivotal for pioneering new frontiers in personalized medicine and fortifying the company's expertise in 3D printing and advanced robotics. [Published On: 2024-01-17]
Strategic Acquisition Enhances Novartis' Precision Medicine Capabilities
Novartis successfully acquired Chinook Therapeutics, a company specializing in precision medicines. This move aligns with Novartis' strategic objective to broaden its portfolio in the precision medicine sector, particularly in developing advanced treatments for kidney diseases. The integration of Chinook's expertise is anticipated to strengthen Novartis' position in the market, facilitating better-targeted and more effective healthcare solutions. [Published On: 2023-08-14]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Personalized Medicine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Personalized Medicine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen, Inc., AstraZeneca, Bayer Ag, BIOGEN INC., Eli Lilly and Company, Exact Sciences Corporation, Exagen Inc, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc., Glaxosmithkline Plc., Illumina, Inc., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Precision Biologics, Inc., QIAGEN GmbH, and Takeda Pharmaceutical Company Limited.
Market Segmentation & Coverage